Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Outsourcing

4,004.787
-145.977-3.52%
Number of Gainers:1
Number of Losers:6
Number of Flat:1
PE:- -
High:4,127.559
Open:4,085.436
Low:3,882.331
Close:4,150.764
Volume:131.63M
Turnover:6.56B
Market Cap:944.37B
Float Cap:393.23B

Loading ...

WuXi Biologics Logs HY Net Profit Attributable RMB 2,439.8 Mln

Reuters
·
Aug 25

WUXI BIO reports 4.3% rise in interim net profit to RMB 2.44 billion

Stock News
·
Aug 25

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

Reuters
·
Aug 25

WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million

THOMSON REUTERS
·
Aug 25

WuXi AppTec (4800亿市值) Faces Cybersecurity Breach; Global Drugmakers Report Recent Hacks

Deep News
·
Aug 25

Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong

Dow Jones
·
Aug 25

Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly

Stock News
·
Aug 25

HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results

Reuters
·
Aug 25

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Stock News
·
Aug 25

Transcenta Holding Announces Extraordinary General Meeting

Reuters
·
Aug 25

Wuxi AppTec Resolves DEL Platform Security Breach, Continues Investigation With Cyber Specialists

Stock News
·
Aug 24

Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition

Reuters
·
Aug 24

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Reuters
·
Aug 24

Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong

Dow Jones
·
Aug 24

AH Share Premium Rankings: Market Close Update for August 24

Stock News
·
Aug 24

Daiwa Raises Pharmaron Target Price to HK$38.5, Boosts Estimates, Keeps 'Buy' Rating

Stock News
·
Aug 24

BofA Securities Raises Pharmaron Target Price to HK$38.4 on CDMO Growth Cycle

Stock News
·
Aug 24

Morgan Stanley Lifts Pharmaron Target Price to HK$35.60, Maintains Overweight Rating

Deep News
·
Aug 23

TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million

Reuters
·
Aug 21

Wuxi Biologics (Cayman) Stock Rallies 2.7% in Hong Kong

Dow Jones
·
Aug 21